INR 113.35
(-3.45%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 109.75 Million INR | -21.27% |
2022 | 1.45 Billion INR | 5.37% |
2021 | 1.37 Billion INR | 42.72% |
2020 | 966.37 Million INR | -27.77% |
2019 | 1.33 Billion INR | -26.31% |
2018 | 1.81 Billion INR | -6.18% |
2017 | 1.93 Billion INR | -1.68% |
2016 | 1.96 Billion INR | 13.26% |
2015 | 1.73 Billion INR | 37.33% |
2014 | 1.26 Billion INR | 15.36% |
2013 | 1.09 Billion INR | 20.74% |
2012 | 908.4 Million INR | 7.97% |
2011 | 841.36 Million INR | -8.76% |
2010 | 922.15 Million INR | 50.03% |
2009 | 614.62 Million INR | 11.68% |
2008 | 550.35 Million INR | 7.67% |
2007 | 511.14 Million INR | 12.32% |
2006 | 455.08 Million INR | 12.56% |
2005 | 404.3 Million INR | 28.93% |
2004 | 313.58 Million INR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 562.36 Million INR | -89.67% |
2024 Q1 | 249.18 Million INR | -9.46% |
2023 FY | 1.14 Billion INR | -21.27% |
2023 Q4 | 275.21 Million INR | -45.23% |
2023 Q1 | 334.76 Million INR | -4.81% |
2023 Q3 | 502.45 Million INR | 77.57% |
2023 Q2 | 282.96 Million INR | -15.47% |
2022 Q3 | 562.58 Million INR | 103.07% |
2022 FY | 1.45 Billion INR | 5.37% |
2022 Q2 | 277.04 Million INR | 5.75% |
2022 Q4 | 351.69 Million INR | -37.49% |
2022 Q1 | 261.99 Million INR | 7.66% |
2021 Q1 | 456.16 Million INR | 97.95% |
2021 FY | 1.37 Billion INR | 42.72% |
2021 Q4 | 243.36 Million INR | -36.18% |
2021 Q3 | 381.34 Million INR | 27.82% |
2021 Q2 | 298.35 Million INR | -34.6% |
2020 Q1 | 167.18 Million INR | -51.21% |
2020 Q2 | 276.47 Million INR | 65.36% |
2020 Q3 | 292.94 Million INR | 5.96% |
2020 Q4 | 230.44 Million INR | -21.33% |
2020 FY | 966.37 Million INR | -27.77% |
2019 Q4 | 342.69 Million INR | 9.5% |
2019 FY | 1.33 Billion INR | -26.31% |
2019 Q3 | 312.97 Million INR | 31.04% |
2019 Q1 | 443.34 Million INR | -52.09% |
2019 Q2 | 238.84 Million INR | -46.13% |
2018 Q4 | 925.37 Million INR | 304.83% |
2018 Q1 | 643.48 Million INR | 0.0% |
2018 Q3 | 228.58 Million INR | -57.75% |
2018 Q2 | 541.04 Million INR | -15.92% |
2018 FY | 1.81 Billion INR | -6.18% |
2017 FY | 1.93 Billion INR | -1.68% |
2016 FY | 1.96 Billion INR | 13.26% |
2016 Q4 | 491.5 Million INR | 0.0% |
2015 Q3 | 327.55 Million INR | -34.94% |
2015 Q4 | 383.65 Million INR | 17.13% |
2015 FY | 1.73 Billion INR | 37.33% |
2015 Q2 | 503.46 Million INR | 69.51% |
2015 Q1 | 297.02 Million INR | -40.16% |
2014 Q2 | 442.62 Million INR | 57.25% |
2014 Q1 | 281.48 Million INR | -3.22% |
2014 FY | 1.26 Billion INR | 15.36% |
2014 Q4 | 496.36 Million INR | 60.14% |
2014 Q3 | 309.95 Million INR | -29.97% |
2013 Q1 | 190.89 Million INR | -21.58% |
2013 Q4 | 290.85 Million INR | 7.67% |
2013 Q3 | 270.13 Million INR | -21.69% |
2013 FY | 1.09 Billion INR | 20.74% |
2013 Q2 | 344.93 Million INR | 80.69% |
2012 Q3 | 232.93 Million INR | 27.93% |
2012 Q4 | 243.42 Million INR | 4.5% |
2012 FY | 908.4 Million INR | 7.97% |
2012 Q1 | 337.43 Million INR | 0.0% |
2012 Q2 | 182.07 Million INR | -46.04% |
2011 FY | 841.36 Million INR | -8.76% |
2010 FY | 922.15 Million INR | 50.03% |
2009 FY | 614.62 Million INR | 11.68% |
2008 FY | 550.35 Million INR | 7.67% |
2007 FY | 511.14 Million INR | 12.32% |
2006 FY | 455.08 Million INR | 12.56% |
2005 FY | 404.3 Million INR | 28.93% |
2004 FY | 313.58 Million INR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Bal Pharma Limited | 389.89 Million INR | 71.851% |
Achyut Healthcare Limited | 1.6 Million INR | -6721.007% |
Alkem Laboratories Limited | 32.83 Billion INR | 99.666% |
Divi's Laboratories Limited | 14.17 Billion INR | 99.225% |
Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 99.838% |
Glenmark Life Sciences Limited | 11.64 Billion INR | 99.057% |
Krebs Biochemicals & Industries Limited | 46.15 Million INR | -137.781% |
Mankind Pharma Limited | 23.15 Billion INR | 99.526% |
Medicamen Biotech Limited | 335.16 Million INR | 67.255% |
Medico Remedies Limited | 161.84 Million INR | 32.188% |
Megasoft Limited | 49.52 Million INR | -121.592% |
Procter & Gamble Health Limited | 2.99 Billion INR | 96.336% |
Piramal Pharma Limited | 19.91 Billion INR | 99.449% |
Sequent Scientific Limited | 2.9 Billion INR | 96.218% |
Sigachi Industries Limited | 579.88 Million INR | 81.074% |
Ajanta Pharma Limited | 30.46 Billion INR | 99.64% |
Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.929% |
Brooks Laboratories Limited | 51.18 Million INR | -114.439% |
Aarti Pharmalabs Limited | 3.07 Billion INR | 96.43% |
Themis Medicare Limited | 782.85 Million INR | 85.981% |
Unichem Laboratories Limited | 6.72 Billion INR | 98.368% |
Hester Biosciences Limited | 908.84 Million INR | 87.924% |
Venus Remedies Limited | 1.91 Billion INR | 94.273% |
Indoco Remedies Limited | 4.74 Billion INR | 97.689% |
Ind-Swift Limited | 946.56 Million INR | 88.405% |
Aarti Drugs Limited | 1.16 Billion INR | 90.599% |
Alpa Laboratories Limited | 156.14 Million INR | 29.714% |
AstraZeneca Pharma India Limited | 2.6 Billion INR | 95.779% |
Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 99.886% |
Granules India Limited | 7.18 Billion INR | 98.472% |
Gufic Biosciences Limited | 1.07 Billion INR | 89.816% |
Hikal Limited | 2.48 Billion INR | 95.586% |
RPG Life Sciences Limited | 1.63 Billion INR | 93.29% |
Suven Pharmaceuticals Limited | 1.4 Billion INR | 92.176% |
Windlas Biotech Limited | 1 Billion INR | 89.096% |
ZIM Laboratories Limited | 1.01 Billion INR | 89.166% |
Ind-Swift Laboratories Limited | 2.12 Billion INR | 94.833% |
IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | 90.012% |
Jubilant Pharmova Limited | 14.45 Billion INR | 99.241% |
Aurobindo Pharma Limited | 39.23 Billion INR | 99.72% |
Bajaj HealthCare Limited | 985.34 Million INR | 88.862% |
Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -577.064% |
Ipca Laboratories Limited | 13.91 Billion INR | 99.211% |
Lasa Supergenerics Limited | 291.17 Million INR | 62.308% |
Laurus Labs Limited | 3.01 Billion INR | 96.355% |
NATCO Pharma Limited | 10.05 Billion INR | 98.909% |
Nectar Lifesciences Limited | 625.55 Million INR | 82.455% |
Shilpa Medicare Limited | 2.18 Billion INR | 94.967% |
Solara Active Pharma Sciences Limited | 4.57 Billion INR | 97.604% |
Torrent Pharmaceuticals Limited | 21.42 Billion INR | 99.488% |
Wanbury Limited | 1.16 Billion INR | 90.546% |
Wockhardt Limited | 6.4 Billion INR | 98.285% |
Strides Pharma Science Limited | 9.16 Billion INR | 98.802% |
Bliss GVS Pharma Limited | 1.41 Billion INR | 92.267% |
Amrutanjan Health Care Limited | 1.09 Billion INR | 90.014% |
Alembic Pharmaceuticals Limited | 15.86 Billion INR | 99.308% |
Eris Lifesciences Limited | 4.94 Billion INR | 97.78% |
Lupin Limited | 95.67 Billion INR | 99.885% |
Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 96.433% |
Syncom Formulations (India) Limited | 942.39 Million INR | 88.354% |
Valiant Laboratories Limited | 36.28 Million INR | -202.433% |
Zydus Lifesciences Limited | 43.17 Billion INR | 99.746% |
FDC Limited | 5.34 Billion INR | 97.948% |
J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | 98.696% |
Novartis India Limited | 470.1 Million INR | 76.654% |
Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | 85.81% |
Neuland Laboratories Limited | 2.92 Billion INR | 96.254% |
Morepen Laboratories Limited | 1.98 Billion INR | 94.478% |
Kilitch Drugs (India) Limited | 412.42 Million INR | 73.389% |
Mangalam Drugs & Organics Limited | 676.14 Million INR | 83.768% |